| 1. |
|
|
| 2. |
|
|
| 3. |
- Hampton, DeeAndria, et al.
(författare)
-
Philanthropy during COVID‐19 : Learnings and recommendations for philanthropic organizations navigating crisis
- 2024
-
Ingår i: Journal of Philanthropy and Marketing. - 2691-1361 .- 2691-1361. ; 29:1
-
Tidskriftsartikel (refereegranskat)abstract
- This practice paper articulates the key learnings for philanthropic organizations based on their experiences of the COVID-19 pandemic. Which actions can philanthropic organizations take to best support community needs during times of crisis? To answer this question, we synthesize information about how philanthropic organizations responded during the early COVID-19 crisis (spring―fall 2020) across 11 countries: Australia, Austria, Finland, Germany, Iceland, Israel, Norway, Sweden, the Republic of Korea, the Russian Federation, and the United States of America. Results indicate four key actions that we recommend philanthropic organizations take during times of crisis: (1) Assess community needs; (2) engage with volunteers and donors; (3) communicate effectively and strategically with volunteers, donors, and the public; and (4) focus on equity.
|
|
| 4. |
|
|
| 5. |
- Lind, Alexandra, et al.
(författare)
-
Ocular findings and growth in 5-year-old preterm children born to mothers with preeclampsia
- 2020
-
Ingår i: Acta Ophthalmologica. - : Wiley. - 1755-375X .- 1755-3768. ; 98:7, s. 671-678
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose To evaluate growth, blood pressure and ophthalmological status in preschool children born preterm to mothers with preeclampsia. Methods In a prospective cohort study, 78 children (34 girls) born preterm without retinopathy of prematurity were examined regarding length/height, weight, head circumference and insulin-like growth factor I (IGF-I) at birth and at 5 years of age. At 5 years, IGF-binding protein 3 and blood pressure were also measured. A detailed ophthalmological examination including ocular dimensions, fundus morphology, visual fields, visual evoked potentials and perceptual visual dysfunction was performed. Children born to preeclamptic mothers (n = 24) were compared to children with non-preeclamptic mothers (n = 54). Results Children exposed to preeclampsia had lower weight (p = 0.0002, mean difference -1.46, 95% CI -2.09; -0.83), length (p = 0.013, -1.10, 95% CI -1.92; -0.23) and IGF-I levels (p = 0.0002, -26.0, 95% CI -36.0; -16.1) at birth compared to non-exposed children. At 5 years of age, the preeclamptic group had larger optic cup areas (p = 0.0006, 0.32, 95% CI 0.15; 0.46, in right eye, p = 0.049, 0.18, 95% CI 0.001; 0.35, in left eye). There was no significant difference between the groups regarding other ophthalmological findings or blood pressure. Children with reduced eye motility had lower neonatal IGF-I levels (p = 0.033, 15.5, 95% CI 1.1; 30.3). Conclusion Preeclampsia was shown to affect growth and IGF-I levels, confirming previous studies. Children exposed to preeclampsia were shown to have larger optic cup areas. Furthermore, lower neonatal IGF-I levels were seen in preterm children with reduced eye motility at 5 years of age.
|
|
| 6. |
|
|
| 7. |
- Rabenstein, M., et al.
(författare)
-
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies
- 2023
-
Ingår i: European Journal of Neurology. - 1351-5101 .- 1468-1331. ; 30:12, s. 3789-3798
-
Tidskriftsartikel (refereegranskat)abstract
- Background and purpose: Hybrid immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develops from a combination of natural infection and vaccine-generated immunity. Multiple sclerosis (MS) disease-modifying therapies (DMTs) have the potential to impact humoral and cellular immunity induced by SARS-CoV-2 vaccination and infection. The aims were to compare antibody and T-cell responses after SARS-CoV-2 mRNA vaccination in persons with MS (pwMS) treated with different DMTs and to assess differences between naively vaccinated pwMS and pwMS with hybrid immunity vaccinated following a previous SARS-CoV-2 infection.Methods: Antibody and T-cell responses were determined in pwMS at baseline and 4 and 12 weeks after the second dose of SARS-CoV-2 vaccination in 143 pwMS with or without previous SARS-CoV-2 infection and 40 healthy controls (HCs). The MS cohort comprised natalizumab (n = 22), dimethylfumarate (n = 23), fingolimod (n = 38), cladribine (n = 30), alemtuzumab (n = 17) and teriflunomide (n = 13) treated pwMS. Immunoglobulin G antibody responses to SARS-CoV-2 antigens were measured using a multiplex bead assay and FluoroSpot was used to assess T-cell responses (interferon gamma and interleukin 13).Results: Humoral and T-cell responses to vaccination were comparable between naively vaccinated HCs and pwMS treated with natalizumab, dimethylfumarate, cladribine, alemtuzumab and teriflunomide, but were suppressed in fingolimod-treated pwMS. Both fingolimod-treated pwMS and HCs vaccinated following a previous SARS-CoV-2 infection had higher antibody levels 4 weeks after vaccination compared to naively vaccinated individuals. Antibody and interferon gamma levels 12 weeks after vaccination were positively correlated with time from last treatment course of cladribine.Conclusion: These findings are of relevance for infection risk mitigation and for vaccination strategies amongst pwMS undergoing DMT.
|
|
| 8. |
|
|
